Author + information
- Received April 12, 2019
- Revision received April 29, 2019
- Accepted April 29, 2019
- Published online July 15, 2019.
- David F. Briceño, MDa,
- Andres Enriquez, MDb,
- Jackson J. Liang, DOa,
- Yasuhiro Shirai, MDa,
- Pasquale Santangeli, MD, PhDa,
- Gustavo Guandalini, MDa,
- Gregory E. Supple, MDa,
- Robert Schaller, DOa,
- Jeffrey Arkles, MDa,
- David S. Frankel, MDa,
- Carlos Tapias, MDc,
- Diego Rodriguez, MDc,
- Luis C. Saenz, MDc,
- David J. Callans, MDa,
- Francis Marchlinski, MDa and
- Fermin C. Garcia, MDa,c,∗ ()
- aElectrophysiology Section, Cardiovascular Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- bFundación Cardioinfantil, Instituto de Cardiología, Centro Internacional de Arritmias Andrea Natale, Bogotá, Colombia
- cHeart Rhythm Service, Queen’s University, Kingston, Ontario, Canada
- ↵∗Address for correspondence:
Dr. Fermin C. Garcia, Section of Cardiac Electrophysiology, Hospital of the University of Pennsylvania, 9 Founders Pavilion, 3400 Spruce Street, Philadelphia, Pennsylvania 19104.
Objectives This study describes the use of septal coronary venous mapping to facilitate substrate characterization and ablation of intramural septal ventricular arrhythmia (VA).
Background Intramural septal VA represents a challenge for substrate definition and catheter ablation.
Methods Between 2015 and 2018, 12 patients with structural heart disease, recurrent VA, and suspected intramural septal substrate underwent a septal coronary venous procedure in which mapping was performed by advancement of a wire into the septal perforator branches of the anterior interventricular vein. A total of 5 patients with idiopathic VA were also included as control subjects to compare substrate characteristics.
Results Patients were 63 ± 14 years of age, and 11 (92%) were men. Most patients with structural heart disease had nonischemic cardiomyopathy (83%). Six patients underwent ablation for premature ventricular contractions (PVC) and 6 for ventricular tachycardia. All patients had larger septal unipolar voltage abnormalities than bipolar voltage abnormalities (mean area 35.3 ± 16.8 cm2 vs. 10.7 ± 8.4 cm2, respectively; p = 0.01), Patients with idiopathic VA had normal voltage. Septal coronary venous mapping revealed low-voltage, fractionated, and multicomponent electrograms in sinus rhythm in all patients with substrate compared to that in patients with idiopathic VA (amplitude 0.9 ± 0.9 mV vs. 4.4 ± 3.7 mV, respectively; p = 0.007; and duration 147 ± 48 ms vs. 92 ± 10 ms, respectively; p = 0.03). Ablation targeted early activation, pace map match, and/or good entrainment sites from intraseptal recording. Over a mean follow-up of 339 ± 240 days, the PVC and insertable cardioverter-defibrillator therapies burden were significantly reduced (from a mean of 22 ± 11% to 4 ± 8%; p = 0.005; and a mean 5 ± 2 to 1 ± 1; p = 0.001, respectively). Most patients (80%) with idiopathic VA remained arrhythmia free.
Conclusions In patients with suspected intramural septal VA, mapping of the septal coronary veins may be helpful to characterize the arrhythmia substrate, identify ablation targets, and guide endocardial ablation.
Supported in part by the Winkelman Family Fund in Cardiovascular Innovation. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Clinical Electrophysiology author instructions page.
- Received April 12, 2019.
- Revision received April 29, 2019.
- Accepted April 29, 2019.
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.